Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A form of congenital disorders of N-linked glycosylation characterized by iris coloboma, cataract, infantile spasms, developmental delay and abnormal coagulation factors. The disease is caused by loss-of-function mutations in the gene ALG2 (9q31.1). Transmission is autosomal recessive.
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 5:40 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ALG2-congenital disorder of glycosylation
Features include always present findings: Hypsarrhythmia, Delayed CNS myelination, Enlarged liver (hepatomegaly), and Severe intellectual disability and others; and common findings: Epicanthus, Decreased body weight, Upslanted palpebral fissure, and Low iron red blood cell count (iron deficiency anemia) and others. 42 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Dystonia, Severe intellectual disability, Enlarged brain ventricles (ventriculomegaly) |
Digestive system | 3 | Enlarged liver (hepatomegaly), Gastroesophageal reflux, Diarrhea |
Head and neck | 3 | Flat face, High palate, Microcephaly |
Eyes | 3 | Nystagmus, Cataract, Visual impairment |
Blood and immune system | 1 | Low iron red blood cell count (iron deficiency anemia) |
Growth and development | 1 | Short stature |
Muscles | 1 | Generalized hypotonia |
Bones and joints | 1 | Joint hypermobility |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Hormones | 1 | Hypothyroidism |
ALG2 encodes ALG2 alpha-1,3/1,6-mannosyltransferase (416 aa). Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. Highest expression in Cells Cultured fibroblasts (46.5 TPM) and Cells EBV-transformed lymphocytes (40.5 TPM).
ALG2-congenital disorder of glycosylation is strongly associated with mutations in the ALG2 gene on chromosome 9.
The ALG2 protein participates in ALG2 72_75delinsSPR, Defective ALG2 causes CDG-1i, and Defective ALG14 causes ALG14-CMS pathways.
ALG2 is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for ALG2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for ALG2-congenital disorder of glycosylation has been reported in the published literature.
Phenotype severity distribution: 13 always present features, 27 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for ALG2-congenital disorder of glycosylation.
203 publications have been identified in PubMed for ALG2-congenital disorder of glycosylation. Research spans Review / Meta-Analysis (44%), Basic Science / Preclinical (39%), and Diagnostic / Biomarker (6%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 75 | 44% |
Laboratory research | 66 | 39% |
Testing and diagnosis research | 10 | 6% |
Disease patterns and progression | 8 | 5% |
Patient case studies | 6 | 4% |
New treatment approaches | 4 | 2% |
Other research | 1 | 1% |
Kim KH (2026). [PMID: 42074215](https://pubmed.ncbi.nlm.nih.gov/42074215/). *Int J Mol Sci*. [Review / Meta-Analysis]
Yi L (2026). [PMID: 41264770](https://pubmed.ncbi.nlm.nih.gov/41264770/). *Protein Cell*. [Review / Meta-Analysis]
Zhu N (2026). [PMID: 41177858](https://pubmed.ncbi.nlm.nih.gov/41177858/). *Sci China Life Sci*. [Basic Science / Preclinical]
Wang T (2026). [PMID: 41808328](https://pubmed.ncbi.nlm.nih.gov/41808328/). *Ann Med*. [Review / Meta-Analysis]
Tawfik CA (2026). [PMID: 41667393](https://pubmed.ncbi.nlm.nih.gov/41667393/). *Ophthalmic Genet*. [Case Report / Case Series]
Weger M (2026). [PMID: 41644694](https://pubmed.ncbi.nlm.nih.gov/41644694/). *Nat Metab*. [Basic Science / Preclinical]
Ünsal Y (2026). [PMID: 39975416](https://pubmed.ncbi.nlm.nih.gov/39975416/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
Chen D (2026). [PMID: 40815461](https://pubmed.ncbi.nlm.nih.gov/40815461/). *Mol Biotechnol*. [Basic Science / Preclinical]
Johannes L (2026). [PMID: 41173705](https://pubmed.ncbi.nlm.nih.gov/41173705/). *Trends Cell Biol*. [Review / Meta-Analysis]
Reynolds G (2026). [PMID: 41392699](https://pubmed.ncbi.nlm.nih.gov/41392699/). *Am J Med Genet A*. [Case Report / Case Series]
AI-curated news mentioning ALG2-congenital disorder of glycosylation
Updated Jul 21, 2026
FDA approved Casgevy CRISPR gene therapy for children as young as 2 with sickle cell disease on July 1, 2026. Here's what families need to know about this milestone. Approximately 5,500 additional American children are now eligible for this established one-time therapy, according to Vertex Pharmaceuticals, Casgevy's developer. Casgevy also covers transfusion-dependent beta-thalassemia in this new age indication. Sickle cell disease is a lifelong inherited blood disorder that warps red blood cells into stiff, crescent shapes that can block blood flow, starving organs and tissues of oxygen. The world's first CRISPR-based gene therapy has been approved for children as young as two years old, opening the possibility of a single, potentially curative treatment to thousands of American children with sickle cell disease before years of organ damage can narrow what medicine can do for them. Families with children aged 2 and older who have sickle cell disease should speak with their pediatric hematologist about whether Casgevy is appropriate to consider at this stage of their child's disease. Ask specifically which authorized treatment centers perform Casgevy in your region. Treatment is available only at specialized sites, and geographic access remains limited. Contact your child's insurance plan or Medicaid office to ask about coverage. Medicaid coverage for gene therapies varies by state, and some states have developed outcomes-based payment models for high-cost therapies. "With today's decision, pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases," said Karim Mikhail, acting director of the Office of Therapeutic Products at the FDA's Center for Biologics Evaluation and Research, according to the FDA press announcement. Casgevy is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy.